Filing Analysis
Delisting Notice
Filed Apr 29, 2026
CRITICAL
Sangamo Therapeutics received a formal delisting notice from Nasdaq on April 28, 2026, after failing to regain compliance with the $1.00 minimum bid price requirement. Trading on the Nasdaq Capital Market will be suspended on May 5, 2026, and the company's common stock is expected to transition to the OTCQB Venture Market.
Red Flags
- Formal delisting determination from a major national exchange (Nasdaq).
- Failure to regain compliance after two 180-day grace periods (totaling approximately one year).
- Immediate trading suspension scheduled for May 5, 2026.
- Transition to the OTCQB Venture Market, which typically involves lower liquidity and reduced institutional interest.
Key Facts
- The Company received a written delisting notice from Nasdaq on April 28, 2026.
- The delisting is due to the stock price remaining below the $1.00 minimum bid price requirement for over 360 days.
- Trading on Nasdaq will be suspended at the open of trading on May 5, 2026.
- Sangamo plans to appeal the decision to a Nasdaq Hearings Panel, but the appeal will not stay the trading suspension.
- The Company has received approval to quote its common stock on the OTCQB Venture Market starting May 5, 2026, under the symbol 'SGMO'.
Regulation FD Disclosure
Filed Mar 30, 2026
LOW
Sangamo Therapeutics announced its financial results for the fiscal year ended December 31, 2025. The disclosure was made via a press release furnished as an exhibit to the 8-K filing.
Key Facts
- The filing reports financial results for the full year ended December 31, 2025.
- The report was filed on March 30, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the results was included as Exhibit 99.1.
- The company is listed on the Nasdaq Capital Market under the ticker SGMO.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.